ReviewFrontiers in oncology2025
Application of artificial intelligence-based stemness index in cancer.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Research progress on the biological function and molecular mechanism of GDF-15 in solid malignant tumors.World journal of surgical oncology · 2026Review
- TRIM29 suppresses malignant progression in lung squamous cell carcinoma by shaping an immunosuppressive tumor microenvironment.Scientific reports · 2026Article
- Diagnostic value of peripheral blood leukocyte parameters, NE-WX, LY-Y, MO-WY, MO-Y, MO-Z, and NE-SFL, in lung cancer.Frontiers in oncology · 2026Article
- Efficacy and safety of secondary induction radiotherapy in locally advanced resectable esophageal squamous cell carcinoma with poor responses to neoadjuvant immunochemotherapy: a retrospective study.Frontiers in immunology · 2026Article
- Construction of a novel risk model for esophageal squamous cell carcinoma associated with purinergic signaling pathways and chemoradiotherapy sensitivity genes.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) exhibit self-renewal and multidirectional differentiation capacities. The stemness of CSCs is the fundamental cause of tumor progression and treatment resistance. The stemness index, evaluating the number and activity of CSCs, is a crucial indicator predicting various aspects of tumor behavior such as growth, metastasis, and prognosis. With the advancements in artificial intelligence (AI), particularly in data analysis and machine learning, the identification and understanding of CSCs' stemness characteristics have improved. The AI-based analysis allows for processing vast datasets and recognizing patterns that assist in comprehending the role of CSCs in cancer development. The utilization of AI to analyze and compute the stemness index holds significant clinical relevance in tumor diagnosis and treatment. This approach provides more precise and personalized information, potentially influencing treatment strategies. Therefore, tailoring treatments specifically targeting CSCs is highly imperative and may enhance therapeutic efficacy and outcomes in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.